{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:19:59Z","timestamp":1793071199185,"version":"4.5.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02633-4","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T15:40:57Z","timestamp":1740325257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Metal nanoparticles as a promising therapeutic approach for prostate cancer diagnosis and therapy: a comprehensive review"],"prefix":"10.1007","volume":"42","author":[{"given":"Mohamed J.","family":"Saadh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajida Ataallah","family":"Khidr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karar H.","family":"Alfarttoosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Bishoyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Shankhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gayathri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Rizaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waam Mohammed","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood Jasem","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M. Ali","family":"Al-Nuaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-024-02844-7","volume":"41","author":"Y Fan","year":"2024","unstructured":"Fan Y, Liu Z, Chen Y, He Z. Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value. Adv Ther. 2024;41:1\u201321.","journal-title":"Adv Ther"},{"issue":"2","key":"2633_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63.","journal-title":"World J Oncol"},{"issue":"17","key":"2633_CR3","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"1","key":"2633_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.21886\/2308-6424-2022-10-1-110-120","volume":"10","author":"VY Startsev","year":"2022","unstructured":"Startsev VY, Shpot EV, Karaev DK, Krivonosov DI. Opportunities for early detection of prostate cancer in young and middle-aged men. Urol Her. 2022;10(1):110\u201320.","journal-title":"Urol Her"},{"key":"2633_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/978-3-662-62426-5_48","volume-title":"Pr\u00e4vention und Gesundheitsf\u00f6rderung","author":"T Kohl","year":"2021","unstructured":"Kohl T, Grabbert M, Heidenreich A. Prostatakrebs-Pr\u00e4valenz, Bedeutung und Implikationen f\u00fcr die Pr\u00e4vention und Gesundheitsf\u00f6rderung. In: Pr\u00e4vention und Gesundheitsf\u00f6rderung. Berlin: Springer; 2021. p. 797\u2013802."},{"key":"2633_CR6","first-page":"414","volume":"7","author":"SB Kanoje","year":"2022","unstructured":"Kanoje SB, Shinde P, Charde MS, Chakole RD. A review on prostate cancer diagnosis and treatment. Int J Sci Dev Res. 2022;7:414.","journal-title":"Int J Sci Dev Res"},{"key":"2633_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.32383\/farmpol\/152041","volume":"78","author":"D Wardecki","year":"2022","unstructured":"Wardecki D, Do\u0142owy M. Prostate cancer\u2014current treatment options. Farm Pol. 2022;78:268.","journal-title":"Farm Pol"},{"key":"2633_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-030-73119-9_16","volume":"1329","author":"S Nagireddy","year":"2021","unstructured":"Nagireddy S, Qureshi R, Best JC, Frech FS, Shah K, Soni Y, Kuchakulla M, Narasimman M, Arora H. Current treatment modalities targeting tumor microenvironment in castration-resistant prostate cancer. Adv Exp Med Biol. 2021;1329:295\u2013323.","journal-title":"Adv Exp Med Biol"},{"key":"2633_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Mousavi SM, Sheykholeslami PN, Fathi M, Saray MM, Aghebati-Maleki L, Jafari R, Zolbanin NM, Jadidi-Niaragh F. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;284: 119132.","journal-title":"Life Sci"},{"key":"2633_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CU9.0000000000000028","volume":"15","author":"J Lyu","year":"2021","unstructured":"Lyu J, Wang M. Commentary: treatment of prostate cancer. Curr Urol. 2021;15:77\u20138.","journal-title":"Curr Urol"},{"key":"2633_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.18565\/urology.2019.6.156-164","volume":"6","author":"DV Chinenov","year":"2020","unstructured":"Chinenov DV, Shpot EV, Chernov YN, Amosov AV, Enikeev DV, Krupinov GE, Petrovskyi NV, Olifirova KP. Minimally invasive techniques of localized prostate cancer. Urologiia. 2020;6:156\u201364.","journal-title":"Urologiia"},{"key":"2633_CR12","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/14656566.2023.2244415","volume":"24","author":"M Mitsogianni","year":"2023","unstructured":"Mitsogianni M, Papatsoris A, Bala VM, Issa H, Moussa M, Mitsogiannis IC. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer. Expert Opin Pharmacother. 2023;24:1765\u201374.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2633_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13(7):632.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2633_CR14","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1111\/cas.14889","volume":"112","author":"J Lim","year":"2021","unstructured":"Lim J, Onozawa M, Saad M, Ong TA, Malek R, Akaza H. Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: comparing between high-and middle-income Asian countries. Cancer Sci. 2021;112(6):2071\u201380.","journal-title":"Cancer Sci"},{"issue":"3","key":"2633_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.21037\/tau.2018.03.07","volume":"7","author":"MD Hurwitz","year":"2018","unstructured":"Hurwitz MD. Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 2018;7(3):390.","journal-title":"Transl Androl Urol"},{"key":"2633_CR16","doi-asserted-by":"publisher","DOI":"10.5222\/GJU.2021.54264","author":"D Kara\u00e7etin","year":"2021","unstructured":"Kara\u00e7etin D. Current approaches in prostate cancer radiotherapy. GJU. 2021. https:\/\/doi.org\/10.5222\/GJU.2021.54264.","journal-title":"GJU"},{"issue":"2","key":"2633_CR17","first-page":"1","volume":"19","author":"\u0130A \u00c7etin","year":"2020","unstructured":"\u00c7etin \u0130A. Current approach in radiation therapy for prostate cancer. \u00dcroonkoloji B\u00fclteni. 2020;19(2):1.","journal-title":"\u00dcroonkoloji B\u00fclteni"},{"key":"2633_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3390\/pharmaceutics15061767","volume":"15","author":"H Wahnou","year":"2023","unstructured":"Wahnou H, Youlyouz-Marfak I, Liagre B, Sol V, Oudghiri M, Duval RE, Limami Y. Shining a light on prostate cancer: photodynamic therapy and combination approaches. Pharmaceutics. 2023;15:1767.","journal-title":"Pharmaceutics"},{"key":"2633_CR19","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"MP Sekhoacha","year":"2022","unstructured":"Sekhoacha MP, Riet K, Motloung P, Gumenku L, Adegoke AM, Mashele SS. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.","journal-title":"Molecules"},{"key":"2633_CR20","first-page":"1","volume":"8","author":"N Dhumal","year":"2023","unstructured":"Dhumal N, Shirote PJ, Ghorpade R, Galande P. Metallic nanoparticles: a novel approach in nanotechnology. Int J Sci Dev Res. 2023;8:1\u20138.","journal-title":"Int J Sci Dev Res"},{"key":"2633_CR21","first-page":"10","volume":"2024","author":"MSB Madhavi","year":"2024","unstructured":"Madhavi MSB. A review on metallic nanoparticles. Int J Sci Res Eng Manag. 2024;2024:10.","journal-title":"Int J Sci Res Eng Manag"},{"key":"2633_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2174\/1567201819666220817110025","volume":"20","author":"S Pawar","year":"2022","unstructured":"Pawar S, Takke A. Regulatory aspects, types, and bioapplications of metallic nanoparticles: a review. Curr Drug Deliv. 2022;20:857.","journal-title":"Curr Drug Deliv"},{"key":"2633_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ma12213602","volume":"12","author":"N Narayan","year":"2019","unstructured":"Narayan N, Meiyazhagan A, Vajtai R. Metal nanoparticles as green catalysts. Materials. 2019;12:1.","journal-title":"Materials"},{"key":"2633_CR24","doi-asserted-by":"publisher","first-page":"113714","DOI":"10.1016\/j.biopha.2022.113714","volume":"155","author":"J Zhao","year":"2022","unstructured":"Zhao J, Zhang C, Wang W, Li C, Mu X, Hu K. Current progress of nanomedicine for prostate cancer diagnosis and treatment. Biomed Pharmacother. 2022;155:113714.","journal-title":"Biomed Pharmacother"},{"key":"2633_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02892-y","volume":"37","author":"S Izadi","year":"2020","unstructured":"Izadi S, Moslehi A, Kheiry H, Karoon Kiani F, Ahmadi A, Masjedi A, Ghani S, Rafiee B, Karpisheh V, Hajizadeh F. Codelivery of HIF-1\u03b1 siRNA and dinaciclib by carboxylated graphene oxide-trimethyl chitosan-hyaluronate nanoparticles significantly suppresses cancer cell progression. Pharm Res. 2020;37:1\u201320.","journal-title":"Pharm Res"},{"key":"2633_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ijbiomac.2021.07.034","volume":"186","author":"AMS Khesht","year":"2021","unstructured":"Khesht AMS, Karpisheh V, Gilan PS, Melnikova LA, Zekiy AO, Mohammadi M, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. Int J Biol Macromol. 2021;186:849\u201363.","journal-title":"Int J Biol Macromol"},{"key":"2633_CR27","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.2174\/1381612826666200721001500","volume":"26","author":"H Yari","year":"2020","unstructured":"Yari H, Gali H, Awasthi V. Nanoparticles for targeting of prostate cancer. Curr Pharm Des. 2020;26:5393.","journal-title":"Curr Pharm Des"},{"key":"2633_CR28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/10717544.2022.2039804","volume":"29","author":"J-J Xu","year":"2022","unstructured":"Xu J-J, Zhang W, Guo Y-W, Chen X-Y, Zhang Y-N. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Deliv. 2022;29:664\u201378.","journal-title":"Drug Deliv"},{"issue":"1","key":"2633_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1568026619666190125145836","volume":"19","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang L, You X, Xian T, Wu J, Pang J. Nanoparticle therapy for prostate cancer: overview and perspectives. Curr Top Med Chem. 2019;19(1):57\u201373.","journal-title":"Curr Top Med Chem"},{"key":"2633_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ijbiomac.2020.11.056","volume":"167","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Afjadi JF, Afjadi MN, Haeri MS, Sough TSA, Asl SH, Edalati M, Atyabi F, Masjedi A, Hajizadeh F. Inhibition of HIF-1\u03b1\/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. Int J Biol Macromol. 2021;167:1006\u201319.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"2633_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84(2):191\u2013206.","journal-title":"Eur Urol"},{"issue":"1","key":"2633_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2633_CR33","first-page":"429","volume":"42","author":"A Moradi","year":"2024","unstructured":"Moradi A, Sahebi U, Nazarian H, Majdi L, Bayat M. Oncogenic MicroRNAs: key players in human prostate cancer pathogenesis, a narrative review. Urol Oncol Semin Orig Invest. 2024;42:429.","journal-title":"Urol Oncol Semin Orig Invest"},{"issue":"8","key":"2633_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1464-410X.2004.04795.x","volume":"93","author":"PC Dagnelie","year":"2004","unstructured":"Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int. 2004;93(8):1139\u201350.","journal-title":"BJU Int"},{"issue":"10","key":"2633_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.7326\/0003-4819-118-10-199305150-00007","volume":"118","author":"KJ Pienta","year":"1993","unstructured":"Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793\u2013803.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2633_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0022-5347(05)64541-7","volume":"168","author":"O Bratt","year":"2002","unstructured":"Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168(3):906\u201313.","journal-title":"J Urol"},{"issue":"6","key":"2633_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1086\/344516","volume":"71","author":"NJ Camp","year":"2002","unstructured":"Camp NJ, Tavtigian SV. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet. 2002;71(6):1475\u20138.","journal-title":"Am J Hum Genet"},{"issue":"21","key":"2633_CR38","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1093\/emboj\/16.21.6355","volume":"16","author":"A Zhou","year":"1997","unstructured":"Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C. Interferon action and apoptosis are defective in mice devoid of 2\u2032, 5\u2032-oligoadenylate-dependent RNase L. EMBO J. 1997;16(21):6355\u201363.","journal-title":"EMBO J"},{"issue":"2","key":"2633_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng994","volume":"32","author":"J Xu","year":"2002","unstructured":"Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32(2):321\u20135.","journal-title":"Nat Genet"},{"issue":"6","key":"2633_CR40","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490\u2013503.","journal-title":"J Clin Oncol"},{"key":"2633_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148.","journal-title":"Eur Urol"},{"issue":"7","key":"2633_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1586\/14737159.2014.936851","volume":"14","author":"VJ Gnanapragasam","year":"2014","unstructured":"Gnanapragasam VJ. Molecular markers to guide primary radical treatment selection in localized prostate cancer. Expert Rev Mol Diagn. 2014;14(7):871\u201381.","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"2633_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"24","key":"2633_CR44","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532\u201342.","journal-title":"JAMA"},{"issue":"1","key":"2633_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70(1):479\u201399.","journal-title":"Annu Rev Med"},{"issue":"3","key":"2633_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41585-020-0287-y","volume":"17","author":"AJ Costello","year":"2020","unstructured":"Costello AJ. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat Rev Urol. 2020;17(3):177\u201388.","journal-title":"Nat Rev Urol"},{"issue":"9","key":"2633_CR47","first-page":"737","volume":"36","author":"M Arianayagam","year":"2007","unstructured":"Arianayagam M, Chang J, Rashid P. Chemotherapy in the treatment of prostate cancer: Is there a role? Aust J General Pract. 2007;36(9):737.","journal-title":"Aust J General Pract"},{"key":"2633_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/modpathol.2017.158","volume":"31","author":"AJ Evans","year":"2018","unstructured":"Evans AJ. Treatment effects in prostate cancer. Mod Pathol. 2018;31:110\u201321.","journal-title":"Mod Pathol"},{"key":"2633_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2023.41.6_suppl.387","volume":"41","author":"CB Nawaf","year":"2023","unstructured":"Nawaf CB, Peng B, Reimers MA, Weimholt C, Slane K, Oppelt PJ, Frankel J, Figenshau RS, Kim EH, Andriole GL. A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. J Clin Oncol. 2023;41:387.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2633_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2217\/fon-2021-1096","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022;18(10):1185\u201398.","journal-title":"Future Oncol"},{"key":"2633_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2672","volume":"42","author":"N Mehra","year":"2024","unstructured":"Mehra N, Voortman J, Wise DR, Calvo E, Piulats JM, Gonzalez-Billalabeitia E, Ortego I, Swami U, Picus J, Karlik M. Phase I\/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:672.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2633_CR52","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Tarlatamab: first approval. Drugs. 2024;84(8):995\u20131003.","journal-title":"Drugs"},{"issue":"1","key":"2633_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","volume":"70","author":"K Yoshimura","year":"2016","unstructured":"Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H. A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol. 2016;70(1):35\u201341.","journal-title":"Eur Urol"},{"key":"2633_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00262-017-1994-y","volume":"66","author":"W Lilleby","year":"2017","unstructured":"Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM. Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother. 2017;66:891\u2013901.","journal-title":"Cancer Immunol Immunother"},{"key":"2633_CR55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/annonc\/mdx370.007","volume":"28","author":"ND Shore","year":"2017","unstructured":"Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, McMullan T, Kraynyak K, Lee J, Sacchetta B, Tagawa ST. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Ann Oncol. 2017;28:272.","journal-title":"Ann Oncol"},{"issue":"7","key":"2633_CR56","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099\u2013105.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2633_CR57","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo ASY, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76(14):1257\u201370.","journal-title":"Prostate"},{"key":"2633_CR58","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00262-017-2027-6","volume":"66","author":"G Sonpavde","year":"2017","unstructured":"Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunol Immunother. 2017;66:1345\u201357.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"2633_CR59","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089\u201394.","journal-title":"J Clin Oncol"},{"key":"2633_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.2017.35.6_suppl.203","volume":"35","author":"KA Autio","year":"2017","unstructured":"Autio KA, Eastham JA, Danila DC, Slovin SF, Morris MJ, Abida W, Laudone VP, Touijer KA, Gopalan A, Wong P. A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC. J Clin Oncol. 2017;35:203.","journal-title":"J Clin Oncol"},{"key":"2633_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/annonc\/mdw372.03","volume":"27","author":"JN Graff","year":"2016","unstructured":"Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Slottke R, Beer TM. First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC). Ann Oncol. 2016;27:244.","journal-title":"Ann Oncol"},{"key":"2633_CR62","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10120-018-0903-1","volume":"22","author":"T Doi","year":"2019","unstructured":"Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer. 2019;22:817\u201327.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2633_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2633_CR64","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40097-022-00504-2","volume":"13","author":"HS Tuli","year":"2023","unstructured":"Tuli HS, Joshi R, Kaur G, Garg VK, Sak K, Varol M, Kaur J, Alharbi SA, Alahmadi TA, Aggarwal D. Metal nanoparticles in cancer: from synthesis and metabolism to cellular interactions. J Nanostruct Chem. 2023;13(3):321\u201348.","journal-title":"J Nanostruct Chem"},{"issue":"10","key":"2633_CR65","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3390\/ph16101410","volume":"16","author":"AF Burlec","year":"2023","unstructured":"Burlec AF, Corciova A, Boev M, Batir-Marin D, Mircea C, Cioanca O, Danila G, Danila M, Bucur AF, Hancianu M. Current overview of metal nanoparticles\u2019 synthesis, characterization, and biomedical applications, with a focus on silver and gold nanoparticles. Pharmaceuticals. 2023;16(10):1410.","journal-title":"Pharmaceuticals"},{"key":"2633_CR66","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1149\/MA2023-01442421mtgabs","volume":"44","author":"F Zamborini","year":"2023","unstructured":"Zamborini F, Nambiar H, Waidyaratne D, Amechi M, Singh R. Unique size-dependent electrochemistry of metal nanoparticles in aqueous and hydrogel environments. ECS Meet Abstr. 2023;44:2421\u20132421.","journal-title":"ECS Meet Abstr"},{"key":"2633_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108288","volume":"101","author":"M Fathi","year":"2021","unstructured":"Fathi M, Bahmanpour S, Barshidi A, Rasouli H, Kiani FK, Khesht AMS, Izadi S, Rashidi B, Kermanpour S, Mokhtarian R. Simultaneous blockade of TIGIT and HIF-1\u03b1 induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. Int Immunopharmacol. 2021;101: 108288.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2633_CR68","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1039\/D0SC04651E","volume":"12","author":"S Stewart","year":"2021","unstructured":"Stewart S, Wei Q, Sun Y. Surface chemistry of quantum-sized metal nanoparticles under light illumination. Chem Sci. 2021;12(4):1227\u201339.","journal-title":"Chem Sci"},{"issue":"1","key":"2633_CR69","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/10717544.2022.2039804","volume":"29","author":"J-J Xu","year":"2022","unstructured":"Xu J-J, Zhang W-C, Guo Y-W, Chen X-Y, Zhang Y-N. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Deliv. 2022;29(1):664\u201378.","journal-title":"Drug Deliv"},{"key":"2633_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120166","volume":"288","author":"FK Kiani","year":"2022","unstructured":"Kiani FK, Izadi S, Dezfouli EA, Ebrahimi F, Mohammadi M, Chalajour H, Bulus MM, Esfahani MN, Karpisheh V, Khesht AMS. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sci. 2022;288: 120166.","journal-title":"Life Sci"},{"issue":"2","key":"2633_CR71","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/0113892010284407240212110745","volume":"26","author":"K Sindhi","year":"2025","unstructured":"Sindhi K, Kanugo A. Recent developments in nanotechnology and immunotherapy for the diagnosis and treatment of pancreatic cancer. Curr Pharm Biotechnol. 2025;26(2):143\u201368.","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"2633_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2317\/0022-8567-96.4.112","volume":"96","author":"M Summer","year":"2024","unstructured":"Summer M, Tahir HM, Ali S, Nawaz S, Abaidullah R, Mumtaz S, Ali A, Gormani AH. Nanobiopesticides as an alternative and sustainable solution to tackle pest outbreaks. J Kansas Entomol Soc. 2024;96(4):112\u201336.","journal-title":"J Kansas Entomol Soc"},{"key":"2633_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.matpr.2023.09.135","volume":"98","author":"G Naga Mallikarjun Rao","year":"2023","unstructured":"Naga Mallikarjun Rao G, Vakkalagadda MRK. A review on synthesis, characterization and applications of nanoparticles in polymer nanocomposites. Mater Today Proc. 2023;98:68.","journal-title":"Mater Today Proc"},{"issue":"1","key":"2633_CR74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12964-023-01213-1","volume":"21","author":"A Khodakarami","year":"2023","unstructured":"Khodakarami A, Kashani MA, Nazer A, Kheshti AM, Rashidi B, Karpisheh V, Masjedi A, Abolhasani S, Izadi S, Bagherifar R. Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide. Cell Commun Signal. 2023;21(1):188.","journal-title":"Cell Commun Signal"},{"key":"2633_CR75","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/B978-0-12-816806-6.00015-7","volume-title":"Polymer science and nanotechnology","author":"AB Asha","year":"2020","unstructured":"Asha AB, Narain R. Nanomaterials properties. In: Polymer science and nanotechnology. Amsterdam: Elsevier; 2020. p. 343\u201359."},{"key":"2633_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-824547-7.00024-2","volume-title":"Sustainable nanotechnology for environmental remediation","author":"R Gupta","year":"2022","unstructured":"Gupta R, Chauhan H, Garg VK, Kataria N. Chemical and physical properties of nanoparticles and hybrid materials. In: Sustainable nanotechnology for environmental remediation. Amsterdam: Elsevier; 2022. p. 199\u2013220."},{"key":"2633_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.mssp.2024.108419","volume":"178","author":"SS Batool","year":"2024","unstructured":"Batool SS, Saleem R, Khan RRM, Saeed Z, Pervaiz M, Summer M. Enhancing photocatalytic performance of zirconia-based nanoparticles: a comprehensive review of factors, doping strategies, and mechanisms. Mater Sci Semicond Process. 2024;178: 108419.","journal-title":"Mater Sci Semicond Process"},{"key":"2633_CR78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/B978-0-12-814182-3.00018-3","volume-title":"Characterization of nanoparticles","author":"DR Baer","year":"2020","unstructured":"Baer DR, Cant DJ, Castner DG, Ceccone G, Engelhard MH, Karakoti AS, M\u00fcller A. Preparation of nanoparticles for surface analysis. In: Characterization of nanoparticles. Amsterdam: Elsevier; 2020. p. 295\u2013347."},{"key":"2633_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103868","volume":"77","author":"AAH Feizi","year":"2022","unstructured":"Feizi AAH, Vakili-Samiani S, Karpisheh V, Masjedi A, Izadi S, Adibfar S, Nikkhoo A, Hojjat-Farsangi M, Atyabi F, Movassaghpour AA. Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine\/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles. J Drug Deliv Sci Technol. 2022;77: 103868.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"2633_CR80","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/21691401.2016.1178134","volume":"45","author":"M Adabi","year":"2017","unstructured":"Adabi M, Naghibzadeh M, Adabi M, Zarrinfard MA, Esnaashari SS, Seifalian AM, Faridi-Majidi R, Tanimowo Aiyelabegan H, Ghanbari H. Biocompatibility and nanostructured materials: applications in nanomedicine. Artif Cells Nanomed Biotechnol. 2017;45(4):833\u201342.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2633_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/00914037.2024.2375337","author":"M Summer","year":"2024","unstructured":"Summer M, Hussain T, Ali S, Khan RRM, Muhammad G, Liaqat I. Exploring the underlying modes of organic nanoparticles in diagnosis, prevention, and treatment of cancer: a review from drug delivery to toxicity. Int J Polym Mater Polym Biomater. 2024. https:\/\/doi.org\/10.1080\/00914037.2024.2375337.","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"2633_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/9783527648122","volume-title":"Microwaves in nanoparticle synthesis: fundamentals and applications","author":"S Horikoshi","year":"2013","unstructured":"Horikoshi S, Serpone N. Microwaves in nanoparticle synthesis: fundamentals and applications. Hoboken: Wiley; 2013."},{"key":"2633_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-319-11262-6_2","volume-title":"Silver nanoparticle applications: in the fabrication and design of medical and biosensing devices","author":"NL Pacioni","year":"2015","unstructured":"Pacioni NL, Borsarelli CD, Rey V, Veglia AV. Synthetic routes for the preparation of silver nanoparticles: a mechanistic perspective. In: Silver nanoparticle applications: in the fabrication and design of medical and biosensing devices. Cham: Springer; 2015. p. 13\u201346."},{"issue":"10","key":"2633_CR84","doi-asserted-by":"publisher","first-page":"14075","DOI":"10.1016\/j.ceramint.2021.01.277","volume":"47","author":"K Adib","year":"2021","unstructured":"Adib K, Sohouli E, Ghalkhani M, Naderi HR, Rezvani Z, Rahimi-Nasrabadi M. Sonochemical synthesis of Ag2WO4\/RGO-based nanocomposite as a potential material for supercapacitors electrodes. Ceram Int. 2021;47(10):14075\u201386.","journal-title":"Ceram Int"},{"key":"2633_CR85","first-page":"6373","volume":"28","author":"M Rahimi-Nasrabadi","year":"2017","unstructured":"Rahimi-Nasrabadi M. Effects of amino acid capping-agents on the size and morphology and photocatalytic properties of BNCTO nanostructures. J Mater Sci: Mater Electron. 2017;28:6373\u20138.","journal-title":"J Mater Sci: Mater Electron"},{"issue":"3","key":"2633_CR86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/or.2023.8496","volume":"49","author":"LJ Castro-Mu\u00f1oz","year":"2023","unstructured":"Castro-Mu\u00f1oz LJ, V\u00e1zquez Ulloa E, Sahlgren C, Lizano M, De La Cruz-Hern\u00e1ndez E, Contreras-Paredes A. Modulating epigenetic modifications for cancer therapy. Oncol Rep. 2023;49(3):59.","journal-title":"Oncol Rep"},{"key":"2633_CR87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-1-4939-6646-2_19","volume":"1530","author":"AR Fernandes","year":"2017","unstructured":"Fernandes AR, Baptista PV. Gene silencing using multifunctionalized gold nanoparticles for cancer therapy. Cancer Nanotechnol Methods Protoc. 2017;1530:319\u201336.","journal-title":"Cancer Nanotechnol Methods Protoc"},{"issue":"9","key":"2633_CR88","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.3390\/molecules190913498","volume":"19","author":"J Baharara","year":"2014","unstructured":"Baharara J, Namvar F, Mousavi M, Ramezani T, Mohamad R. Anti-angiogenesis effect of biogenic silver nanoparticles synthesized using saliva officinalis on chick chorioalantoic membrane (CAM). Molecules. 2014;19(9):13498\u2013508.","journal-title":"Molecules"},{"issue":"2","key":"2633_CR89","first-page":"00173","volume":"7","author":"R Elliott","year":"2018","unstructured":"Elliott R, Santra S. Nanomedicine: tackling undruggable non-small cell lung cancer. J Nanomed Res. 2018;7(2):00173.","journal-title":"J Nanomed Res"},{"key":"2633_CR90","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","volume":"357","author":"S Anthiya","year":"2023","unstructured":"Anthiya S, \u00d6zt\u00fcrk SC, Yanik H, Tavukcuoglu E, \u015eahin A, Datta D, Charisse K, \u00c1lvarez DM, Loza MI, Calvo A. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release. 2023;357:67\u201383.","journal-title":"J Control Release"},{"issue":"5","key":"2633_CR91","first-page":"328","volume":"39","author":"XD Liu","year":"2021","unstructured":"Liu XD, Wang C, Meng XJ, Pan XF, Li J, Niu DS, Chen ZJ. A non-targeted metabolomics study on urine of occupational exposure people with titanium dioxide nanoparticles. Chin J Ind Hyg Occup Dis. 2021;39(5):328\u201332.","journal-title":"Chin J Ind Hyg Occup Dis"},{"key":"2633_CR92","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.2147\/IJN.S258699","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Mao W, Wang Z, Li X, Xiong Y, Lu H, Wang X, Yin H, Cao X, Xin H. Enhanced anti-brain metastasis from non-small cell lung cancer of osimertinib and doxorubicin co-delivery targeted nanocarrier. Int J Nanomed. 2020;15:5491\u2013501.","journal-title":"Int J Nanomed"},{"key":"2633_CR93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/978-3-319-16555-4_13","volume":"2015","author":"AKR Lytton-Jean","year":"2015","unstructured":"Lytton-Jean AKR, Kauffman KJ, Kaczmarek JC, Langer R. Cancer nanotherapeutics in clinical trials. Nanotechnol Based Precis Tools Detect Treat Cancer. 2015;2015:293\u2013322.","journal-title":"Nanotechnol Based Precis Tools Detect Treat Cancer"},{"key":"2633_CR94","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11095-010-0178-7","volume":"28","author":"JD Heidel","year":"2011","unstructured":"Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer therapy. Pharm Res. 2011;28:187\u201399.","journal-title":"Pharm Res"},{"issue":"1","key":"2633_CR95","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","volume":"24","author":"M Wang","year":"2025","unstructured":"Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges. Mol Cancer. 2025;24(1):26.","journal-title":"Mol Cancer"},{"issue":"4","key":"2633_CR96","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2633_CR97","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1021\/nl504044p","volume":"15","author":"H Chen","year":"2015","unstructured":"Chen H, Wang GD, Chuang Y-J, Zhen Z, Chen X, Biddinger P, Hao Z, Liu F, Shen B, Pan Z. Nanoscintillator-mediated X-ray inducible photodynamic therapy for in vivo cancer treatment. Nano Lett. 2015;15(4):2249\u201356.","journal-title":"Nano Lett"},{"key":"2633_CR98","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.snb.2018.03.179","volume":"267","author":"C Rodriguez","year":"2018","unstructured":"Rodriguez C, Torres-Costa V, Ahumada O, Cebri\u00e1n V, G\u00f3mez-Abad C, D\u00edaz A, Silv\u00e1n MM. Gold nanoparticle triggered dual optoplasmonic-impedimetric sensing of prostate-specific antigen on interdigitated porous silicon platforms. Sens Actuators B Chem. 2018;267:559\u201364.","journal-title":"Sens Actuators B Chem"},{"key":"2633_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ab.2017.08.001","volume":"536","author":"M Pal","year":"2017","unstructured":"Pal M, Khan K. Detection of prostate cancer risk factor immunosensor based deposition of graphene layer decorated gold nanoparticles. Anal Biochem. 2017;536:51.","journal-title":"Anal Biochem"},{"issue":"3","key":"2633_CR100","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bios.2004.11.016","volume":"21","author":"L Huang","year":"2005","unstructured":"Huang L, Reekmans G, Saerens D, Friedt J-M, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron. 2005;21(3):483\u201390.","journal-title":"Biosens Bioelectron"},{"issue":"7","key":"2633_CR101","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/nprot.2017.031","volume":"12","author":"S Harmsen","year":"2017","unstructured":"Harmsen S, Wall MA, Huang R, Kircher MF. Cancer imaging using surface-enhanced resonance Raman scattering nanoparticles. Nat Protoc. 2017;12(7):1400\u201314.","journal-title":"Nat Protoc"},{"issue":"1","key":"2633_CR102","doi-asserted-by":"publisher","first-page":"11238","DOI":"10.1038\/s41598-017-11680-5","volume":"7","author":"N Sattarahmady","year":"2017","unstructured":"Sattarahmady N, Rahi A, Heli H. A signal-on built in-marker electrochemical aptasensor for human prostate-specific antigen based on a hairbrush-like gold nanostructure. Sci Rep. 2017;7(1):11238.","journal-title":"Sci Rep"},{"issue":"12","key":"2633_CR103","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.procbio.2015.10.007","volume":"50","author":"D Dhamecha","year":"2015","unstructured":"Dhamecha D, Jalalpure S, Jadhav K. Doxorubicin functionalized gold nanoparticles: characterization and activity against human cancer cell lines. Process Biochem. 2015;50(12):2298\u2013306.","journal-title":"Process Biochem"},{"issue":"7","key":"2633_CR104","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1021\/nn901877h","volume":"4","author":"D Kim","year":"2010","unstructured":"Kim D, Jeong YY, Jon S. A drug-loaded aptamer\u2212 gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4(7):3689\u201396.","journal-title":"ACS Nano"},{"issue":"1","key":"2633_CR105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/nnm.15.183","volume":"11","author":"L-C Tsai","year":"2016","unstructured":"Tsai L-C, Hsieh H-Y, Lu K-Y, Wang S-Y, Mi F-L. EGCG\/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. Nanomedicine. 2016;11(1):9\u201330.","journal-title":"Nanomedicine"},{"issue":"37","key":"2633_CR106","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/20\/37\/375101","volume":"20","author":"W Roa","year":"2009","unstructured":"Roa W, Zhang X, Guo L, Shaw A, Hu X, Xiong Y, Gulavita S, Patel S, Sun X, Chen J. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology. 2009;20(37): 375101.","journal-title":"Nanotechnology"},{"issue":"7","key":"2633_CR107","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/pharmaceutics13071094","volume":"13","author":"A Radaic","year":"2021","unstructured":"Radaic A, Joo NE, Jeong S-H, Yoo S II, Kotov N, Kapila YL. Phosphatidylserine-gold nanoparticles (PS-AuNP) induce prostate and breast cancer cell apoptosis. Pharmaceutics. 2021;13(7):1094.","journal-title":"Pharmaceutics"},{"key":"2633_CR108","first-page":"1","volume":"20215","author":"AG Reznikov","year":"2015","unstructured":"Reznikov AG, Salivonyk OA, Sotkis AG, Shuba YM. Assessment of gold nanoparticle effect on prostate cancer LNCaP cells. Exp Oncol. 2015;20215:1.","journal-title":"Exp Oncol"},{"issue":"13","key":"2633_CR109","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1039\/C6TB00082G","volume":"4","author":"KA Fitzgerald","year":"2016","unstructured":"Fitzgerald KA, Rahme K, Guo J, Holmes JD, O\u2019Driscoll CM. Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer\u2013synthesis, physicochemical characterisation and in vitro evaluation. J Mater Chem B. 2016;4(13):2242\u201352.","journal-title":"J Mater Chem B"},{"issue":"11\u201312","key":"2633_CR110","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jgm.2810","volume":"16","author":"A Ekin","year":"2014","unstructured":"Ekin A, Karatas OF, Culha M, Ozen M. Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. J Gene Med. 2014;16(11\u201312):331\u20135.","journal-title":"J Gene Med"},{"issue":"5","key":"2633_CR111","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.nano.2014.12.016","volume":"11","author":"T Wolfe","year":"2015","unstructured":"Wolfe T, Chatterjee D, Lee J, Grant JD, Bhattarai S, Tailor R, Goodrich G, Nicolucci P, Krishnan S. Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomed Nanotechnol Biol Med. 2015;11(5):1277\u201383.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"2633_CR112","first-page":"753","volume-title":"Nanomedicine in Cancer","author":"N Chanda","year":"2017","unstructured":"Chanda N, Kan P, Watkinson LD, Shukla R, Zambre A, Carmack TL, Engelbrecht H, Lever JR, Katti K, Fent GM. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. In: Nanomedicine in Cancer. USA: Jenny Stanford Publishing; 2017. p. 753\u201374."},{"key":"2633_CR113","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ab.2014.09.022","volume":"469","author":"Y Li","year":"2015","unstructured":"Li Y, Han J, Chen R, Ren X, Wei Q. Label electrochemical immunosensor for prostate-specific antigen based on graphene and silver hybridized mesoporous silica. Anal Biochem. 2015;469:76\u201382.","journal-title":"Anal Biochem"},{"key":"2633_CR114","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bios.2015.12.080","volume":"79","author":"H Ma","year":"2016","unstructured":"Ma H, Li X, Yan T, Li Y, Zhang Y, Wu D, Wei Q, Du B. Electrochemiluminescent immunosensing of prostate-specific antigen based on silver nanoparticles-doped Pb (II) metal-organic framework. Biosens Bioelectron. 2016;79:379\u201385.","journal-title":"Biosens Bioelectron"},{"issue":"3","key":"2633_CR115","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00604-023-05680-8","volume":"190","author":"H Nasrollahpour","year":"2023","unstructured":"Nasrollahpour H, Khalilzadeh B, Naseri A, Mamaghani S, Isildak I, Rashidi M-R. Chitosan\/luminol\/AgNPs nanocomposite for electrochemiluminescent determination of prostate-specific antigen. Microchim Acta. 2023;190(3):90.","journal-title":"Microchim Acta"},{"issue":"1","key":"2633_CR116","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ab.2012.11.012","volume":"434","author":"H Wang","year":"2013","unstructured":"Wang H, Zhang Y, Yu H, Wu D, Ma H, Li H, Du B, Wei Q. Label-free electrochemical immunosensor for prostate-specific antigen based on silver hybridized mesoporous silica nanoparticles. Anal Biochem. 2013;434(1):123\u20137.","journal-title":"Anal Biochem"},{"issue":"14","key":"2633_CR117","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1039\/D1AN00822F","volume":"146","author":"L Zhu","year":"2021","unstructured":"Zhu L, Yin Z, Lv Z, Li M, Tang D. Ultrasensitive photoelectrochemical immunoassay for prostate-specific antigen based on silver nanoparticle-triggered ion-exchange reaction with ZnO\/CdS nanorods. Analyst. 2021;146(14):4487\u201394.","journal-title":"Analyst"},{"issue":"12","key":"2633_CR118","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.3390\/s21124099","volume":"21","author":"H-M Kim","year":"2021","unstructured":"Kim H-M, Kim J, Bock S, An J, Choi Y-S, Pham X-H, Cha MG, Seong B, Kim W, Kim Y-H. Silver-assembled silica nanoparticles in lateral flow immunoassay for visual inspection of prostate-specific antigen. Sensors. 2021;21(12):4099.","journal-title":"Sensors"},{"key":"2633_CR119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12645-013-0034-7","volume":"4","author":"M Hossu","year":"2013","unstructured":"Hossu M, Ma L, Zou X, Chen W. Enhancement of biophoton emission of prostate cancer cells by Ag nanoparticles. Cancer Nanotechnol. 2013;4:21\u20136.","journal-title":"Cancer Nanotechnol"},{"issue":"5","key":"2633_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22474","volume":"34","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang T, Chen S, Qi S, Zhang Z, Xu Y. Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells. J Biochem Mol Toxicol. 2020;34(5): e22474.","journal-title":"J Biochem Mol Toxicol"},{"key":"2633_CR121","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00775-019-01729-3","volume":"25","author":"R Kumari","year":"2020","unstructured":"Kumari R, Saini AK, Kumar A, Saini RV. Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction. J Biol Inorg Chem. 2020;25:23\u201337.","journal-title":"J Biol Inorg Chem"},{"key":"2633_CR122","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s12011-020-02255-z","volume":"199","author":"SP Singh","year":"2021","unstructured":"Singh SP, Mishra A, Shyanti RK, Singh RP, Acharya A. Silver nanoparticles synthesized using Carica papaya leaf extract (AgNPs-PLE) causes cell cycle arrest and apoptosis in human prostate (DU145) cancer cells. Biol Trace Elem Res. 2021;199:1316\u201331.","journal-title":"Biol Trace Elem Res"},{"key":"2633_CR123","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-024-04293-3","author":"H Tahir","year":"2024","unstructured":"Tahir H, Rashid F, Ali S, Summer M, Afzal M. Synthesis, characterization, phytochemistry, and therapeutic potential of Azadirachta indica conjugated silver nanoparticles: a comprehensive study on antidiabetic and antioxidant properties. Biol Trace Elem Res. 2024. https:\/\/doi.org\/10.1007\/s12011-024-04293-3.","journal-title":"Biol Trace Elem Res"},{"issue":"6","key":"2633_CR124","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/jemt.24509","volume":"87","author":"TA Mughal","year":"2024","unstructured":"Mughal TA, Ali S, Mumtaz S, Summer M, Saleem MZ, Hassan A, Hameed MU. Evaluating the biological (antidiabetic) potential of TEM, FTIR, XRD, and UV-spectra observed berberis lyceum conjugated silver nanoparticles. Microsc Res Tech. 2024;87(6):1286\u2013305.","journal-title":"Microsc Res Tech"},{"key":"2633_CR125","first-page":"1","volume":"200","author":"SMA El-Sheikh","year":"2021","unstructured":"El-Sheikh SMA, Edrees N, El-Sayed H, Khamis T, Arisha AH, Metwally MMM, Eleiwa NZ, Galal AAA. Could cisplatin loading on biosynthesized silver nanoparticles improve its therapeutic efficacy on human prostate cancer cell line and reduce its in vivo nephrotoxic effects? Biol Trace Elem Res. 2021;200:1\u20139.","journal-title":"Biol Trace Elem Res"},{"issue":"1","key":"2633_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-024-09506-5","volume":"51","author":"S Hatami Zharabad","year":"2024","unstructured":"Hatami Zharabad S, Mohammadian M, Zohdi Aghdam R, Hassanzadeh Dizaj M, Behrouzkia Z. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells. Mol Biol Rep. 2024;51(1):1\u201310.","journal-title":"Mol Biol Rep"},{"key":"2633_CR127","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.2147\/IJN.S364862","volume":"17","author":"M Morais","year":"2022","unstructured":"Morais M, Machado V, Dias F, Figueiredo P, Palmeira C, Martins G, Fernandes R, Malheiro AR, Mikkonen KS, Teixeira AL. Glucose-functionalized silver nanoparticles as a potential new therapy agent targeting hormone-resistant prostate cancer cells. Int J Nanomed. 2022;17:4321.","journal-title":"Int J Nanomed"},{"key":"2633_CR128","doi-asserted-by":"publisher","first-page":"9091","DOI":"10.2147\/IJN.S447645","volume":"19","author":"M Morais","year":"2024","unstructured":"Morais M, Dias F, Figueiredo P, Tavares I, Escudeiro C, Teixeira MR, Teixeira A, Lisboa J, Mikkonen KS, Teixeira AL. Silver nanoparticles (AgNPs) uptake by caveolae-dependent endocytosis is responsible for their selective effect towards castration resistant prostate cancer. Int J Nanomed. 2024;19:9091\u2013107.","journal-title":"Int J Nanomed"},{"key":"2633_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00449-024-03023-2","volume":"47","author":"K Marathe","year":"2024","unstructured":"Marathe K, Naik J, Maheshwari V. Synthesis, characterisation and in vitro anticancer activity of conjugated protease inhibitor\u2013silver nanoparticles (AgNPs\u2013PI) against human breast MCF-7 and prostate PC-3 cancer cell lines. Bioprocess Biosyst Eng. 2024;47:1\u201312.","journal-title":"Bioprocess Biosyst Eng"},{"key":"2633_CR130","doi-asserted-by":"publisher","first-page":"105869","DOI":"10.1016\/j.tiv.2024.105869","volume":"99","author":"ICG Santos","year":"2024","unstructured":"Santos ICG, de Oliveira ML, Silva RC, Sant\u2019Anna C. Assessment of silver nanoparticles\u2019 antitumor effects: Insights into cell number, viability, and morphology of glioblastoma and prostate cancer cells. Toxicol Vitro. 2024;99:105869.","journal-title":"Toxicol Vitro"},{"issue":"4","key":"2633_CR131","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.2310\/7290.2007.00025","volume":"6","author":"RE Serda","year":"2007","unstructured":"Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging. 2007;6(4):7290\u20132007.","journal-title":"Mol Imaging"},{"key":"2633_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122008","volume":"624","author":"C Liolios","year":"2022","unstructured":"Liolios C, Koutsikou TS, Salvanou E-A, Kapiris F, Machairas E, Stampolaki M, Kolocouris A, Efthimiadou E\u039a, Bouziotis P. Synthesis and in vitro proof-of-concept studies on bispecific iron oxide magnetic nanoparticles targeting PSMA and GRP receptors for PET\/MR imaging of prostate cancer. Int J Pharm. 2022;624: 122008.","journal-title":"Int J Pharm"},{"issue":"2","key":"2633_CR133","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cmmi.1514","volume":"8","author":"M Abdolahi","year":"2013","unstructured":"Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, Boutry S, Muller RN. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging. 2013;8(2):175\u201384.","journal-title":"Contrast Media Mol Imaging"},{"key":"2633_CR134","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s11051-009-9681-3","volume":"12","author":"AL Martin","year":"2010","unstructured":"Martin AL, Hickey JL, Ablack AL, Lewis JD, Luyt LG, Gillies ER. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanopart Res. 2010;12:1599\u2013608.","journal-title":"J Nanopart Res"},{"key":"2633_CR135","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.2147\/IJN.S324354","volume":"16","author":"K Karnas","year":"2021","unstructured":"Karnas K, Str\u0105czek T, Kapusta C, Lekka M, Duli\u0144ska-Litewka J, Karewicz A. Specific binding of novel SPION-based system bearing anti-N-cadherin antibodies to prostate tumor cells. Int J Nanomed. 2021;16:6537\u201352.","journal-title":"Int J Nanomed"},{"issue":"6","key":"2633_CR136","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.eururo.2006.11.023","volume":"52","author":"M Johannsen","year":"2007","unstructured":"Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Wald\u00f6fner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol. 2007;52(6):1653\u201362.","journal-title":"Eur Urol"},{"key":"2633_CR137","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1245\/s10434-014-4024-8","volume":"21","author":"A Winter","year":"2014","unstructured":"Winter A, Woenkhaus J, Wawroschek F. A novel method for intraoperative sentinel lymph node detection in prostate cancer patients using superparamagnetic iron oxide nanoparticles and a handheld magnetometer: the initial clinical experience. Ann Surg Oncol. 2014;21:4390\u20136.","journal-title":"Ann Surg Oncol"},{"key":"2633_CR138","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.2147\/IJN.S173182","volume":"2018","author":"A Winter","year":"2018","unstructured":"Winter A, Kowald T, Paulo TS, Goos P, Engels S, Gerullis H, Schiffmann J, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging and magnetometer-guided intraoperative detection in prostate cancer using superparamagnetic iron oxide nanoparticles. Int J Nanomed. 2018;2018:6689\u201398.","journal-title":"Int J Nanomed"},{"issue":"4","key":"2633_CR139","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.clinimag.2009.01.013","volume":"33","author":"RW Ross","year":"2009","unstructured":"Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging. 2009;33(4):301\u20135.","journal-title":"Clin Imaging"},{"issue":"4","key":"2633_CR140","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/RCT.0b013e318136e194","volume":"32","author":"C-S Li","year":"2008","unstructured":"Li C-S, Harisinghani MG, Lin W-C, Braschi M, Hahn PF, Mueller PR. Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer. J Comput Assist Tomogr. 2008;32(4):523\u20138.","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"2633_CR141","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ejca.2012.09.034","volume":"49","author":"M Triantafyllou","year":"2013","unstructured":"Triantafyllou M, Studer UE, Birkh\u00e4user FD, Fleischmann A, Bains LJ, Petralia G, Christe A, Froehlich JM, Thoeny HC. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and\/or prostate cancer. Eur J Cancer. 2013;49(3):616\u201324.","journal-title":"Eur J Cancer"},{"key":"2633_CR142","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fphar.2019.01123","volume":"10","author":"W Gei\u00dfen","year":"2019","unstructured":"Gei\u00dfen W, Engels S, Aust P, Schiffmann J, Gerullis H, Wawroschek F, Winter A. Diagnostic accuracy of magnetometer-guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in intermediate-and high-risk prostate cancer using the magnetic activity of sentinel nodes. Front Pharmacol. 2019;10:1123.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2633_CR143","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.eururo.2008.12.034","volume":"55","author":"HC Thoeny","year":"2009","unstructured":"Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE. Combined ultrasmall superparamagnetic particles of iron oxide\u2013enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55(4):761\u20139.","journal-title":"Eur Urol"},{"issue":"5","key":"2633_CR144","doi-asserted-by":"publisher","first-page":"9573","DOI":"10.3390\/ijms16059573","volume":"16","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, Zhang Z, Duan Y. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int J Mol Sci. 2015;16(5):9573\u201387.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2633_CR145","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.31557\/APJCP.2023.24.6.2089","volume":"24","author":"D Jafari-Gharabaghlou","year":"2023","unstructured":"Jafari-Gharabaghlou D, Jadid MFS, Jahanban R, Rahimi M, Farajollahi MM, Mohsenzadegan M, Zarghami N. Fabrication of antibody conjugated super magnetic oxide nanoparticles for early detection of prostate cancer. Asian Pac J Cancer Prev. 2023;24(6):2089.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"2633_CR146","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/bab.2012","volume":"68","author":"W Zhang","year":"2021","unstructured":"Zhang W, Li K, Guo J, Ma T, Wang D, Shi S, Gopinath SCB, Gu D. Sensitive identification of prostate-specific antigen by iron oxide nanoparticle antibody conjugates on the gap-finger electrode surface. Biotechnol Appl Biochem. 2021;68(4):896\u2013901.","journal-title":"Biotechnol Appl Biochem"},{"issue":"12","key":"2633_CR147","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/cancers14122909","volume":"14","author":"A Kader","year":"2022","unstructured":"Kader A, Kaufmann JO, Mangarova DB, Moeckel J, Brangsch J, Adams LC, Zhao J, Reimann C, Saatz J, Traub H. Iron oxide nanoparticles for visualization of prostate cancer in MRI. Cancers. 2022;14(12):2909.","journal-title":"Cancers"},{"issue":"3","key":"2633_CR148","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/nnm.14.122","volume":"10","author":"BWC Tse","year":"2015","unstructured":"Tse BWC, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, Khatri A, Liu T, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2015;10(3):375\u201386.","journal-title":"Nanomedicine"},{"issue":"4","key":"2633_CR149","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1109\/TNB.2014.2328868","volume":"13","author":"Z Hajikarimi","year":"2014","unstructured":"Hajikarimi Z, Khoei S, Khoee S, Mahdavi SR. Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5-fluorouracil and mega-voltage X-ray radiation in DU145 prostate cancer cell line. IEEE Trans Nanobiosci. 2014;13(4):403\u20138.","journal-title":"IEEE Trans Nanobiosci"},{"issue":"5","key":"2633_CR150","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/09553002.2014.888104","volume":"90","author":"S Khoei","year":"2014","unstructured":"Khoei S, Mahdavi SR, Fakhimikabir H, Shakeri-Zadeh A, Hashemian A. The role of iron oxide nanoparticles in the radiosensitization of human prostate carcinoma cell line DU145 at megavoltage radiation energies. Int J Radiat Biol. 2014;90(5):351\u20136.","journal-title":"Int J Radiat Biol"},{"issue":"11","key":"2633_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202000607","volume":"17","author":"M Erkisa","year":"2020","unstructured":"Erkisa M, Ari F, Ulku I, Khodadust R, Yar Y, Yagci Acar H, Ulukaya E. Etoposide loaded SPION-PNIPAM nanoparticles improve the in vitro therapeutic outcome on metastatic prostate cancer cells via enhanced apoptosis. Chem Biodivers. 2020;17(11): e2000607.","journal-title":"Chem Biodivers"},{"issue":"14","key":"2633_CR152","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1039\/D2BM00107A","volume":"10","author":"K Onbasli","year":"2022","unstructured":"Onbasli K, Erk\u0131sa M, Demirci G, Muti A, Ulukaya E, Sennaroglu A, Acar HY. The improved killing of both androgen-dependent and independent prostate cancer cells by etoposide loaded SPIONs coupled with NIR irradiation. Biomater Sci. 2022;10(14):3951\u201362.","journal-title":"Biomater Sci"},{"issue":"4","key":"2633_CR153","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/02656736.2015.1005178","volume":"31","author":"A Attaluri","year":"2015","unstructured":"Attaluri A, Kandala SK, Wabler M, Zhou H, Cornejo C, Armour M, Hedayati M, Zhang Y, DeWeese TL, Herman C. Magnetic nanoparticle hyperthermia enhances radiation therapy: a study in mouse models of human prostate cancer. Int J Hyperth. 2015;31(4):359\u201374.","journal-title":"Int J Hyperth"},{"key":"2633_CR154","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.03.071","volume":"144","author":"PKB Nagesh","year":"2016","unstructured":"Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B. 2016;144:8\u201320.","journal-title":"Colloids Surf B"},{"issue":"14","key":"2633_CR155","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1016\/j.biomaterials.2013.01.062","volume":"34","author":"AS Wadajkar","year":"2013","unstructured":"Wadajkar AS, Menon JU, Tsai Y-S, Gore C, Dobin T, Gandee L, Kangasniemi K, Takahashi M, Manandhar B, Ahn J-M. Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles. Biomaterials. 2013;34(14):3618\u201325.","journal-title":"Biomaterials"},{"issue":"15","key":"2633_CR156","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/smll.201100472","volume":"7","author":"MK Yu","year":"2011","unstructured":"Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011;7(15):2241\u20139.","journal-title":"Small"},{"issue":"37","key":"2633_CR157","doi-asserted-by":"publisher","first-page":"12692","DOI":"10.1039\/C7DT02139A","volume":"46","author":"D Bonvin","year":"2017","unstructured":"Bonvin D, Bastiaansen JAM, Stuber M, Hofmann H, Ebersold MM. Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer. Dalton Trans. 2017;46(37):12692\u2013704.","journal-title":"Dalton Trans"},{"key":"2633_CR158","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.bios.2015.10.058","volume":"77","author":"E Spain","year":"2016","unstructured":"Spain E, Gilgunn S, Sharma S, Adamson K, Carthy E, O\u2019Kennedy R, Forster RJ. Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody. Biosens Bioelectron. 2016;77:759\u201366.","journal-title":"Biosens Bioelectron"},{"key":"2633_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00216-021-03827-1","volume":"414","author":"X Cao","year":"2022","unstructured":"Cao X, Liu M, Zhao M, Li J, Xia J, Zou T, Wang Z. Synergetic PtNP@ Co3O4 hollow nanopolyhedrals as peroxidase-like nanozymes for the dual-channel homogeneous biosensing of prostate-specific antigen. Anal Bioanal Chem. 2022;414:1\u201312.","journal-title":"Anal Bioanal Chem"},{"key":"2633_CR160","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.aca.2014.03.040","volume":"825","author":"J Lan","year":"2014","unstructured":"Lan J, Xu W, Wan Q, Zhang X, Lin J, Chen J, Chen J. Colorimetric determination of sarcosine in urine samples of prostatic carcinoma by mimic enzyme palladium nanoparticles. Anal Chim Acta. 2014;825:63\u20138.","journal-title":"Anal Chim Acta"},{"key":"2633_CR161","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1007\/s11051-011-0439-3","volume":"13","author":"RM Taylor","year":"2011","unstructured":"Taylor RM, Huber DL, Monson TC, Ali AMS, Bisoffi M, Sillerud LO. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res. 2011;13:4717\u201329.","journal-title":"J Nanopart Res"},{"key":"2633_CR162","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S34381","author":"RM Taylor","year":"2012","unstructured":"Taylor RM, Sillerud LO. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomed. 2012. https:\/\/doi.org\/10.2147\/IJN.S34381.","journal-title":"Int J Nanomed"},{"issue":"4","key":"2633_CR163","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/polym11040733","volume":"11","author":"S Gurunathan","year":"2019","unstructured":"Gurunathan S, Jeyaraj M, Kang M-H, Kim J-H. Graphene oxide\u2013platinum nanoparticle nanocomposites: a suitable biocompatible therapeutic agent for prostate cancer. Polymers. 2019;11(4):733.","journal-title":"Polymers"},{"issue":"4","key":"2633_CR164","doi-asserted-by":"publisher","first-page":"1601120","DOI":"10.1002\/adhm.201601120","volume":"6","author":"M Laprise-Pelletier","year":"2017","unstructured":"Laprise-Pelletier M, Lagueux J, C\u00f4t\u00e9 MF, LaGrange T, Fortin MA. Low-dose prostate cancer brachytherapy with radioactive palladium-gold nanoparticles. Adv Healthcare Mater. 2017;6(4):1601120.","journal-title":"Adv Healthcare Mater"},{"issue":"16","key":"2633_CR165","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1080\/07391102.2018.1546619","volume":"37","author":"Z Sorinezami","year":"2019","unstructured":"Sorinezami Z, Mansouri-Torshizi H, Aminzadeh M, Ghahghaei A, Jamgohari N, Heidari Majd M. Synthesis of new ultrasonic-assisted palladium oxide nanoparticles: an in vitro evaluation on cytotoxicity and DNA\/BSA binding properties. J Biomol Struct Dyn. 2019;37(16):4238\u201350.","journal-title":"J Biomol Struct Dyn"},{"key":"2633_CR166","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.colsurfb.2018.05.051","volume":"169","author":"RK Thapa","year":"2018","unstructured":"Thapa RK, Soe ZC, Ou W, Poudel K, Jeong J-H, Jin SG, Ku SK, Choi H-G, Lee YM, Yong CS. Palladium nanoparticle-decorated 2-D graphene oxide for effective photodynamic and photothermal therapy of prostate solid tumors. Colloids Surf B. 2018;169:429\u201337.","journal-title":"Colloids Surf B"},{"issue":"3","key":"2633_CR167","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1039\/C3AN01987J","volume":"139","author":"Y-D Zhu","year":"2014","unstructured":"Zhu Y-D, Peng J, Jiang L-P, Zhu J-J. Fluorescent immunosensor based on CuS nanoparticles for sensitive detection of cancer biomarker. Analyst. 2014;139(3):649\u201355.","journal-title":"Analyst"},{"issue":"4","key":"2633_CR168","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1021\/acsami.5b10285","volume":"8","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Wang H, Wang L, Zhu J, Jiang W. Cascade signal amplification based on copper nanoparticle-reported rolling circle amplification for ultrasensitive electrochemical detection of the prostate cancer biomarker. ACS Appl Mater Interfaces. 2016;8(4):2573\u201381.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2633_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2024.125811","volume":"272","author":"S Zhang","year":"2024","unstructured":"Zhang S, Tang X, Zang L, Zhao L. Carbon quantum dots (CQDs)-sensitized CdS\/CuInS2 heterojunction as a photoelectrochemical biosensing platform for highly sensitive detection of prostate-specific antigen. Talanta. 2024;272: 125811.","journal-title":"Talanta"},{"issue":"14","key":"2633_CR170","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2217\/nnm-2018-0062","volume":"13","author":"H Cai","year":"2018","unstructured":"Cai H, Xie F, Mulgaonkar A, Chen L, Sun X, Hsieh J-T, Peng F, Tian R, Li L, Wu C. Bombesin functionalized 64Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine. 2018;13(14):1695\u2013705.","journal-title":"Nanomedicine"},{"key":"2633_CR171","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jphotobiol.2016.06.008","volume":"161","author":"PR Prasad","year":"2016","unstructured":"Prasad PR, Kanchi S, Naidoo EB. In-vitro evaluation of copper nanoparticles cytotoxicity on prostate cancer cell lines and their antioxidant, sensing and catalytic activity: one-pot green approach. J Photochem Photobiol B. 2016;161:375\u201382.","journal-title":"J Photochem Photobiol B"},{"issue":"9","key":"2633_CR172","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1039\/C9BM01905G","volume":"8","author":"VL Silva","year":"2020","unstructured":"Silva VL, Kaassis A, Dehsorkhi A, Koffi C-R, Severic M, Abdelhamid M, Nyimanu D, Morris CJ. Enhanced selectivity, cellular uptake, and in vitro activity of an intrinsically fluorescent copper\u2013tirapazamine nanocomplex for hypoxia targeted therapy in prostate cancer. Biomater Sci. 2020;8(9):2420\u201333.","journal-title":"Biomater Sci"},{"issue":"48","key":"2633_CR173","doi-asserted-by":"publisher","first-page":"41118","DOI":"10.1021\/acsami.8b14940","volume":"10","author":"W Chen","year":"2018","unstructured":"Chen W, Yang W, Chen P, Huang Y, Li F. Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug-resistant prostate cancers. ACS Appl Mater Interfaces. 2018;10(48):41118\u201328.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2633_CR174","doi-asserted-by":"publisher","first-page":"102042","DOI":"10.1016\/j.nano.2019.102042","volume":"21","author":"K Poudel","year":"2019","unstructured":"Poudel K, Thapa RK, Gautam M, Ou W, Soe ZC, Gupta B, Ruttala HB, Thuy HN, Dai PC, Jeong J-H. Multifaceted NIR-responsive polymer-peptide-enveloped drug-loaded copper sulfide nanoplatform for chemo-phototherapy against highly tumorigenic prostate cancer. Nanomed Nanotechnol Biol Med. 2019;21:102042.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"2","key":"2633_CR175","first-page":"64","volume":"7","author":"Z Ghasemian","year":"2015","unstructured":"Ghasemian Z, Shahbazi-Gahrouei D, Manouchehri S. Cobalt zinc ferrite nanoparticles as a potential magnetic resonance imaging agent: an in vitro study. Avicenna J Med Biotechnol. 2015;7(2):64.","journal-title":"Avicenna J Med Biotechnol"},{"issue":"11","key":"2633_CR176","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/bios12110931","volume":"12","author":"SM El-Sheikh","year":"2022","unstructured":"El-Sheikh SM, Sheta SM, Salem SR, Abd-Elzaher MM, Basaleh AS, Labib AA. Prostate-specific antigen monitoring using nano zinc (II) metal-organic framework-based optical biosensor. Biosensors. 2022;12(11):931.","journal-title":"Biosensors"},{"key":"2633_CR177","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.msec.2014.10.062","volume":"46","author":"A Meidanchi","year":"2015","unstructured":"Meidanchi A, Akhavan O, Khoei S, Shokri AA, Hajikarimi Z, Khansari N. ZnFe2O4 nanoparticles as radiosensitizers in radiotherapy of human prostate cancer cells. Mater Sci Eng C. 2015;46:394\u20139.","journal-title":"Mater Sci Eng C"},{"issue":"14","key":"2633_CR178","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1039\/C7RA10997K","volume":"8","author":"P Samutprasert","year":"2018","unstructured":"Samutprasert P, Chiablaem K, Teeraseranee C, Phaiyarin P, Pukfukdee P, Pienpinijtham P, Svasti J, Palaga T, Lirdprapamongkol K, Wanichwecharungruang S. Epigallocatechin gallate-zinc oxide co-crystalline nanoparticles as an anticancer drug that is non-toxic to normal cells. RSC Adv. 2018;8(14):7369\u201376.","journal-title":"RSC Adv"},{"issue":"2","key":"2633_CR179","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/jcrt.JCRT_232_17","volume":"17","author":"A Azhdari","year":"2021","unstructured":"Azhdari A, Jalal R. Zinc oxide nanofluids: the influence of modality combinations on prostate cancer DU145 cells. J Cancer Res Ther. 2021;17(2):393\u2013400.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"2633_CR180","doi-asserted-by":"publisher","first-page":"217","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-3.18452","volume":"44","author":"PA Virych","year":"2022","unstructured":"Virych PA, Zadvornyi TV, Borikun TV, Lykhova OO, Chumachenko VA, Pavlenko VA, Kutsevol NV, Lukianova NY. Effects of dextran-graft-polyacrylamide\/ZnO nanoparticles on prostate cancer cell lines in vitro. Exp Oncol. 2022;44(3):217\u201321.","journal-title":"Exp Oncol"},{"key":"2633_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122998","volume":"640","author":"JC Pieretti","year":"2023","unstructured":"Pieretti JC, Freire BM, Armentano GM, de Melo SB, Batista BL, Carneiro-Ramos MS, Seabra AB. Chronic exposure to nitric oxide sensitizes prostate cancer cells and improved ZnO\/CisPt NPs cytotoxicity and selectivity. Int J Pharm. 2023;640: 122998.","journal-title":"Int J Pharm"},{"issue":"1","key":"2633_CR182","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1166\/jnn.2017.12444","volume":"17","author":"J Fu","year":"2017","unstructured":"Fu J, Zeng X, He N. Comparative cytotoxicity induced by zinc oxide nanoparticles in human prostate cells. J Nanosci Nanotechnol. 2017;17(1):196\u2013202.","journal-title":"J Nanosci Nanotechnol"},{"issue":"1","key":"2633_CR183","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/toxres\/tfad127","volume":"13","author":"F Motafeghi","year":"2024","unstructured":"Motafeghi F, Mortazavi P, Shokrzadeh M. Anticancer activity of zinc oxide nanoparticles on prostate and colon cancer cell line. Toxicol Res. 2024;13(1):127.","journal-title":"Toxicol Res"},{"issue":"22","key":"2633_CR184","doi-asserted-by":"publisher","first-page":"2207077","DOI":"10.1002\/smll.202207077","volume":"19","author":"H Wang","year":"2023","unstructured":"Wang H, Guan Y, Li C, Chen J, Yue S, Qian J, Dai B, Jiang C, Wen C, Wen L. PEGylated manganese\u2013zinc ferrite nanocrystals combined with intratumoral implantation of micromagnets enabled synergetic prostate cancer therapy via ferroptotic and immunogenic cell death. Small. 2023;19(22):2207077.","journal-title":"Small"},{"key":"2633_CR185","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1007\/s11095-014-1313-7","volume":"31","author":"H Rouhani","year":"2014","unstructured":"Rouhani H, Sepehri N, Montazeri H, Khoshayand MR, Ghahremani MH, Ostad SN, Atyabi F, Dinarvand R. Zinc protoporphyrin polymeric nanoparticles: potent heme oxygenase inhibitor for cancer therapy. Pharm Res. 2014;31:2124\u201339.","journal-title":"Pharm Res"},{"issue":"4","key":"2633_CR186","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1039\/C6TX00054A","volume":"5","author":"R Dunpall","year":"2016","unstructured":"Dunpall R, Revaprasadu N. An in vitro and in vivo bio-interaction responses and biosafety evaluation of novel Au\u2013ZnTe core\u2013shell nanoparticles. Toxicol Res. 2016;5(4):1078\u201389.","journal-title":"Toxicol Res"},{"issue":"1","key":"2633_CR187","first-page":"e13450","volume":"52","author":"SMG Rahimi Kalateh","year":"2020","unstructured":"Rahimi Kalateh SMG, Karimi E, Oskoueian E, Homayouni-Tabrizi M. Anticancer properties of green-synthesised zinc oxide nanoparticles using Hyssopus officinalis extract on prostate carcinoma cells and its effects on testicular damage and spermatogenesis in Balb\/C mice. Andrologia. 2020;52(1):e13450.","journal-title":"Andrologia"},{"key":"2633_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113313","volume":"226","author":"B Zhou","year":"2023","unstructured":"Zhou B, Jia B-X, Zhang M-J, Tan Y-J, Liang W-Y, Gan X, Li H-T, Yang X, Shen X-C. Zn2+-interference and H2S-mediated gas therapy based on ZnS-tannic acid nanoparticles synergistic enhancement of cell apoptosis for specific treatment of prostate cancer. Colloids Surf B. 2023;226: 113313.","journal-title":"Colloids Surf B"},{"key":"2633_CR189","doi-asserted-by":"publisher","first-page":"11719","DOI":"10.2147\/IJN.S485106","volume":"2024","author":"P Virych","year":"2024","unstructured":"Virych P, Virych P, Prokopiuk V, Onishchenko A, Ischenko M, Doroschuk V, Kurovska V, Tkachenko A, Kutsevol N. Dextran-graft-polyacrylamide\/zinc oxide nanoparticles inhibit of cancer cells in vitro and in vivo. Int J Nanomed. 2024;2024:11719\u201343.","journal-title":"Int J Nanomed"},{"key":"2633_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2022.339852","volume":"1210","author":"X Gao","year":"2022","unstructured":"Gao X, Niu T, Xia Q, Hu B, Zhao Z, Feng X, Yang J, Tang B, Xu K. Au\u2013Se bonded nanoprobe for prostate specific antigen detection in serum. Anal Chim Acta. 2022;1210: 339852.","journal-title":"Anal Chim Acta"},{"issue":"27","key":"2633_CR191","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1016\/j.biomaterials.2011.05.032","volume":"32","author":"L Kong","year":"2011","unstructured":"Kong L, Yuan Q, Zhu H, Li Y, Guo Q, Wang Q, Bi X, Gao X. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt\/Mdm2\/AR controlled apoptosis. Biomaterials. 2011;32(27):6515\u201322.","journal-title":"Biomaterials"},{"key":"2633_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-017-0276-3","volume":"15","author":"P Sonkusre","year":"2017","unstructured":"Sonkusre P, Cameotra SS. Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation. J Nanobiotechnol. 2017;15:1\u201312.","journal-title":"J Nanobiotechnol"},{"key":"2633_CR193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-020-01850-7","volume":"18","author":"G Liao","year":"2020","unstructured":"Liao G, Tang J, Wang D, Zuo H, Zhang Q, Liu Y, Xiong H. Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16. World J Surg Oncol. 2020;18:1\u201311.","journal-title":"World J Surg Oncol"},{"key":"2633_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.685784","volume":"11","author":"Y An","year":"2021","unstructured":"An Y, Zhao J. Functionalized selenium nanotherapeutics synergizes with zoledronic acid to suppress prostate cancer cell growth through induction of mitochondria-mediated apoptosis and cell cycle S phase arrest. Front Oncol. 2021;11: 685784.","journal-title":"Front Oncol"},{"issue":"14","key":"2633_CR195","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1039\/D0TB00390E","volume":"8","author":"A Barbanente","year":"2020","unstructured":"Barbanente A, Nadar RA, Degli Esposti L, Palazzo B, Iafisco M, Van Den Beucken JJJP, Leeuwenburgh SCG, Margiotta N. Platinum-loaded, selenium-doped hydroxyapatite nanoparticles selectively reduce proliferation of prostate and breast cancer cells co-cultured in the presence of stem cells. J Mater Chem B. 2020;8(14):2792\u2013804.","journal-title":"J Mater Chem B"},{"issue":"23","key":"2633_CR196","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.3390\/nano13232999","volume":"13","author":"C Bissardon","year":"2023","unstructured":"Bissardon C, Proux O, Gazze SA, Filhol O, Toubhans B, Sauz\u00e9at L, Bouchet S, Lewis AR, Maffeis T, Hazemann J-L. Intracellular fate of sub-toxic concentration of functionalized selenium nanoparticles in aggressive prostate cancer cells. Nanomaterials. 2023;13(23):2999.","journal-title":"Nanomaterials"},{"issue":"1","key":"2633_CR197","doi-asserted-by":"publisher","first-page":"101","DOI":"10.32604\/or.2023.044741","volume":"32","author":"R Ghorbani","year":"2023","unstructured":"Ghorbani R, Gharbavi M, Sharafi A, Rismani E, Rezaeejam H, Mortazavi Y, Johari B. Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells. Oncol Res. 2023;32(1):101.","journal-title":"Oncol Res"},{"key":"2633_CR198","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3389\/fonc.2019.01541","volume":"9","author":"P Sonkusre","year":"2020","unstructured":"Sonkusre P. Specificity of biogenic selenium nanoparticles for prostate cancer therapy with reduced risk of toxicity: an in vitro and in vivo study. Front Oncol. 2020;9:1541.","journal-title":"Front Oncol"},{"issue":"2","key":"2633_CR199","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/bbb\/zbaa089","volume":"85","author":"G Liao","year":"2021","unstructured":"Liao G, Ma H, Li Y, Sheng Y, Chen C. Selenium nanoparticles inhibit tumor metastasis in prostate cancer through upregulated miR-155-5p-related pathway. Biosci Biotechnol Biochem. 2021;85(2):287\u201396.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"9","key":"2633_CR200","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/pharmaceutics16091230","volume":"16","author":"Y Zou","year":"2024","unstructured":"Zou Y, Xu H, Wu X, Liu X, Zhao J. Enhancing radiotherapy sensitivity in prostate cancer with lentinan-functionalized selenium nanoparticles: mechanistic insights and therapeutic potential. Pharmaceutics. 2024;16(9):1230.","journal-title":"Pharmaceutics"},{"key":"2633_CR201","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0035","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Patra CR. Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics. Future Sci OA. 2017. https:\/\/doi.org\/10.4155\/fsoa-2017-0035.","journal-title":"Future Sci OA"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02633-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02633-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02633-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:33:26Z","timestamp":1743554006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02633-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":201,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02633-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All of the authors consent for this article publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work the authors used Wordvice AI in order to proofreading and grammar checking. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"83"}}